Isomorphic Labs, Alphabet’s closely watched AI startup, has signed its first pharma partnerships, and will work with Eli Lilly and Novartis in deals that could be worth $3 billion, CEO Demis Hassabis exclusively told Endpoints News.
Since its founding in November 2021, Isomorphic has quickly become a leading figure in the fast-growing AI biotech space. The Alphabet subsidiary is applying Google DeepMind’s biology research — particularly its protein-structure predicting model AlphaFold — to drug discovery. Hassabis is CEO of Google DeepMind, where he oversees Alphabet’s AI efforts, as well as CEO of Isomorphic, which now employs about 90 people across its London headquarters and an office in Lausanne, Switzerland.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
